HMS Capital Management LLC Buys 702 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

HMS Capital Management LLC grew its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 12.0% in the 3rd quarter, Holdings Channel.com reports. The firm owned 6,549 shares of the medical equipment provider’s stock after purchasing an additional 702 shares during the period. HMS Capital Management LLC’s holdings in Zimmer Biomet were worth $707,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Private Advisor Group LLC boosted its position in shares of Zimmer Biomet by 2.2% during the first quarter. Private Advisor Group LLC now owns 10,846 shares of the medical equipment provider’s stock valued at $1,431,000 after buying an additional 236 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Zimmer Biomet by 7.6% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 52,214 shares of the medical equipment provider’s stock worth $6,668,000 after purchasing an additional 3,682 shares during the period. Fidelis Capital Partners LLC purchased a new stake in shares of Zimmer Biomet during the first quarter valued at $69,000. Nordea Investment Management AB grew its holdings in shares of Zimmer Biomet by 11.4% in the first quarter. Nordea Investment Management AB now owns 15,154 shares of the medical equipment provider’s stock worth $2,006,000 after purchasing an additional 1,551 shares during the last quarter. Finally, Financial Counselors Inc. increased its stake in Zimmer Biomet by 5.6% in the 1st quarter. Financial Counselors Inc. now owns 5,006 shares of the medical equipment provider’s stock worth $661,000 after buying an additional 264 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

ZBH has been the topic of a number of research analyst reports. Oppenheimer dropped their target price on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 15th. JPMorgan Chase & Co. decreased their target price on Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating for the company in a research report on Monday, September 16th. Truist Financial increased their price target on Zimmer Biomet from $112.00 to $117.00 and gave the stock a “hold” rating in a research report on Friday, November 1st. Wolfe Research assumed coverage on shares of Zimmer Biomet in a research note on Tuesday, September 10th. They issued a “peer perform” rating for the company. Finally, Robert W. Baird reduced their price objective on shares of Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $124.11.

Zimmer Biomet Trading Up 0.5 %

Shares of Zimmer Biomet stock opened at $108.92 on Wednesday. The firm has a market capitalization of $21.68 billion, a price-to-earnings ratio of 20.71, a PEG ratio of 1.99 and a beta of 1.02. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 12-month low of $101.47 and a 12-month high of $133.90. The firm’s 50 day simple moving average is $106.72 and its two-hundred day simple moving average is $110.58.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.74. The firm had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.65 earnings per share. Analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Shareholders of record on Monday, September 30th were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date of this dividend was Monday, September 30th. Zimmer Biomet’s payout ratio is presently 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.